Abstract
Background Disease-modifying therapies (DMTs) have become the mainstay of treatment for relapsing forms of multiple sclerosis (MS), reducing relapse rates and slowing disease progression.
Objectives To determine whether or not available MS DMTs have demonstrated an increase in safety, efficacy, and tolerability over time.
Methods Results from pivotal phase III trials of approved MS DMTs were used to create a dataset of relevant outcomes. Common endpoints analyzed include annualized relapse rates (ARR), rates of serious adverse events (SAE), and rates of discontinuation due to adverse events. Trial comparator, active or placebo, was also documented. Descriptive statistics and Fisher exact tests were performed on outcomes stratified by recency of pivotal trials.
Results On visual inspection, there was a trend of decrease in ARR. A significant relationship was seen between recent approvals and trial design with an active comparator (p=0.004), as well as between recent approvals and ARR (p=0.020). No significance was found between recent approvals and SAE (p=0.138), formulation and discontinuation (p=0.559), or recent approvals and formulation (p=0.352).
Conclusion DMTs for relapsing forms of MS increased in efficacy over time. Oral therapies offered similar tolerability to other routes of administration. Further research is warranted to identify if these clinical trial findings translate to real world evidence.
What was already known
The number of FDA approved disease-modifying therapies for multiple sclerosis has been steadily increasing. Available routes of administration include injectable, oral, and infusions.
These medications are proven to be effective in reducing MS relapse rates and slowing overall disease progression, with varying degrees of safety and tolerability.
The comparative efficacy of these therapies varies, with certain medications often deemed high efficacy.
What this study adds
We used published phase III trial results for each medication to provide a direct comparison between each medication’s efficacy, safety, and tolerability at time of approval.
Our analysis demonstrates a trend in increasing efficacy of available therapies along with the use of active comparators for controls in disease modifying treatments for multiple sclerosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Credit Author Statement: Kyle Valker: Conceptualization, Methodology, Formal analysis, Investigation, Writing - Original Draft, Visualization Kangho Suh: Conceptualization, Methodology, Formal analysis, Writing - Review & Editing, Visualization, Supervision
Conflict of Interests: The authors declare no relevant conflicts of interest or financial relationships.
Funding Support: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
All data produced in the present work are contained in the manuscript
